Dsm IP Assets B.v.

Joseph Schwager

Daniel Raederstorff

Goede Schueler

Szabolcs Peter

Christof Wehrli

Jaroslav A Kralovec

Peter Weber

Swen Wolfram

Claus Kilpert

Karin Wertz

Bernd Mussler

Weerasinghe M Indrasena

Nathalie Richard

Elisabeth Stoecklin

Stephanie Krammer-Lukas

Volker Spitzer

Karine Wertz

Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver&#x2014;known as non-alcoholic fatty liver disease (NAFLD)&#x2014;and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.

Treatment for non-alcoholic fatty liver diseases

The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver&#x2014;known as non-alcoholic fatty liver disease (NAFLD)&#x2014;and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.

Treating conditions associated with increased eotaxin with 25-hydroxyvitamin D3

Compositions containing a combination of hydroxytyrosol and resveratrol or liqustilide or (&#x2212;)-epigallocatechin gallate or honokiol or genistein orbark extract or a combination of oleuropein and resveratrol or ligustilide are used to treat inflammatory disorders.

Compositions

The present invention relates to novel composition for the treatment, co-treatment or prevention of inflammatory disorders comprising an effective amount of carnosic acid 12-methylether.

The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Nutraceutical and pharmaceutical compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders

Compositions including, as the active ingredients, resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from epigallocatechin gallate (EGCG), genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. Also disclosed, are methods of making such compositions including admixing resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from EGCG, genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. Methods for the treatment or prevention of inflammatory diseases including administering to a subject in need of such treatment resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from epigallocatechin gallate (EGCG), genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are also disclosed.

Growing community of inventors

Basel, Switzerland

Joseph Schwager